- $1.52bn
- $1.20bn
- $411.33m
Innoviva Q2 revenue rises on higher net product sales
Brief: Innoviva Q2 Royalty Revenue USD 56.334 Million
Brief: Nortiva Bio Launches To Develop Long-Acting Oral Medicines
Brief: Innoviva Q1 Royalty Revenue USD 55.167 Million
Innoviva Q4 revenue up 25%, net income soars
Brief: Innoviva Q4 Royalty Revenue USD 54.896 Million
US FDA approves Innoviva's oral antibiotic for gonorrhea (updated)
US FDA approves Innoviva's oral antibiotic for common sexually transmitted infections
Brief: FDA Approved Nuzolvence (Zoliflodacin) To Treat Uncomplicated Urogenital Gonorrhea
Innoviva Q3 revenue up 20%, net income surges
Brief: Innoviva Q3 Royalty Revenue USD 59.896 Million
Brief: Antheia Appoints Eric d'Esparbes as Chief Financial Officer
Innoviva Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Innoviva Q2 Royalty Revenue USD 63.88 Million
Brief: ZEVTERA(Ceftobiprole), An Advanced-Generation Cephalosporin Antibiotic Now Commercially Available In The U.S. To Treat Three Types Of Bacterial Infections
Innoviva Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Innoviva Q1 Royalty Revenue USD 57.807 Million
Health Rounds: Appendectomy appears to reduce ulcerative colitis relapses
Innoviva Inc reports results for the quarter ended December 31 - Earnings Summary